This study aims to demonstrate the sensitivity and specificity of the Curesponse Ex Vivo Organ Culture (EVOC) model for predicting a patient’s clinical response to a specific cancer therapy.

The EVOC is a 3D tissue culture that will be grown from a patient’s cancerous tissue taken from an ultrasound or CT guided biopsy. The 3D tissue culture once grown will be treated with a range of anticancer agents (i.e. chemotherapy) including the chemotherapeutic agent that will be given to the patient by their clinician. The EVOC models prediction on the patient’s response to standard therapy will be communicated to the research team and compared to the patient’s actual clinical; radiological and biochemical response to therapy from which it will be assessed how accurately the 3D model predicted the patient overall response to treatment.

 The study is a phase II multicentre study with a sample size of 248 patients with suspected or confirmed advanced or metastatic cancer in whom a least on lesion is accessible for biopsy.